Background
==========

Diabetic nephropathy (DN) represents one of the leading causes of end-stage renal disease. Unlike diabetic retinopathy, with up to 80% incidence in diabetes patients with more than 20 years\' diagnoses \[[@B1]\], DN affects approximately one third of type 1 diabetes patients during their lifetime, at times irrespective of the glycemic control \[[@B2]\]. These findings taken together with results of familial studies \[[@B3]\], point to the existence of genetic susceptibility to the renal lesions caused by chronic hyperglycemia.

Oxidative stress is currently recognized as a major pathogenic factor of cellular damage caused by hyperglycemia, being considered the final common pathway through which hyperglycemia-related pathways (polyol, advanced glycation end products, protein kinase C and hexosamine) can trigger the chronic complications of diabetes \[[@B4]\]. NOX/NADPH oxidases catalyse NADPH-dependent reduction of O~2~to O~2~^•-^, generating reactive oxygen species (ROS). NOX1, NOX2 and NOX4 are isoforms expressed in the kidney \[[@B5]\] whose activation requires association with subunit p22phox, encoded by the *CYBA*gene. Increased expression of p22phox was described in animal models of DN \[[@B6]\].

Acting in the opposite direction, glutathione (GSH) is one of the main endogenous antioxidants whose plasmatic concentrations were reported to be reduced in diabetes patients \[[@B7]\]. GSH synthesis requires the glutamate-cysteine ligase enzyme (γ-GCL) in the first and rate-limiting step for its production. This enzyme is a heterodimer composed by a heavy catalytic subunit, encoded by the *GCLC*gene, as well as a light regulatory subunit \[[@B8]\]. GSH regulates ROS concentrations via reactions catalyzed by glutathione peroxidases (GPX), such as the plasmatic GPX (GPX3) \[[@B9]\].

Given the role of oxidative stress in the etiopathogenesis of diabetic complications, we examined the association between the presence of renal disease in type 1 diabetes patients and functional single nucleotide polymorphisms (SNPs) in the promoter region of three genes related to cellular redox balance: (1) -675 T → A in *CYBA*(unregistered), where the T allele is associated with higher phagocytic NADPH oxidase activity \[[@B10]\], (2) -129 C → T in *GCLC*(rs17883901), where the T allele determines a lower promoter activity \[[@B8]\] and -65 T → C in *GPX3*(rs8177412), where the C allele is present in a haplotype associated with a lower promoter transcriptional activity \[[@B9]\].

Methods
=======

A total of 401 type 1 diabetes patients and 188 non-diabetic subjects age and gender matched were included between October 2004 and February 2011. The study was carried out in compliance with the Institutional Ethics Committee and the Declaration of Helsinki, with informed consent being given to each participant. Inclusion criterion was diabetes duration ≥ 10 years. DN status was determined by measurements of urinary albumin-to-creatinine ratio (ACR) or urinary albumin excretion rate (UAER). Patients presenting persistent macroalbuminuria (\> 300 mg/g of creatinine or \> 200 μg/min) or proteinuria (\> 500 mg/24 h) were classified as having overt DN (n = 104) and patients without overt DN (n = 196) presented persistent normoalbuminuria. Patients with microalbuminuria were excluded from this analysis. Patients were also stratified according to Modification of Diet in Renal Disease (MDRD)-estimated GFR: ≥ 60 mL (n = 265) or \< 60 mL/min/1.73 m^2^(n = 136). All patients presenting autoimmune diseases and HIV or HCV infection were excluded from the study, as well as patients with overt DN or GFR \< 60 mL/min/1.73 m^2^who did not present diabetic retinopathy.

Hypertension was defined as blood pressure \> 140/90 mmHg on two occasions or use of antihypertensive drugs. UAER was measured in 24-h urine samples by immunoturbidimetry and ACR was measured in spot urine samples using nephelometry, in at least two samples collected over the preceding 6 months. HbA~1C~, creatinine, triglycerides, HDL and LDL-cholesterol were measured as described \[[@B11]\].

*GCLC*-129 C → T (rs17883901; location 6:53410037) was determined by PCR-RFLP as previously described \[[@B8]\], *GPX3*-65 T → C (rs8177412; location 5: 150400087) was genotyped by sequencing of PCR products (5\' CCTGACTTCCACCTCTCTGC 3\' and 5\' CGCCCTCCCCGCTGCTCCTC 3\') on an ABI3130DNA sequencer (Applied Biosystems). *CYBA*-675 A → T (unregistered; location 16:88718096) \[[@B10]\] was genotyped by PCR using specific primers (sense: 5\'-GCGCTGGCTCACCAC-3\' and antisense: 5\'-ACTGGGAAAGCACAGAATGCA-3\') and fluorescent-labelled probes (*VIC*: 5\'-CCTCCCGAACCCAGG-3\' and *FAM*: 5\'-CCTCCCGTACCCAGG-3\') (TaqMan, Applied Biosystems). Genotyping success rates were 100% for the *GCLC*and *GPX3*SNPs and 98% for the *CYBA*SNP. We achieved 100% concordance in the analysis of duplicate samples (15% of total) for all SNPs (the SNP evaluated by RFLP was double genotyped by direct sequencing).

Statistical analyses were performed using JMP 8.0 (JMP SAS Institute Inc). Pearson\'s χ^2^test was used to compare genotype frequencies between non-diabetic and diabetic groups. Mann-Whitney and Fisher\'s χ^2^test were used to compare continuous and categorical variables, respectively. Magnitude of association was estimated using odds ratios (OR) and adjusted OR was estimated by logistic regression for possible confounders (sex, age at diagnosis, diabetes duration, hypertension, triglyceride and cholesterol levels, and HbA~1C~). P values \< 0.05 were considered significant. Power calculations were carried out with the CaTS power calculator \[[@B12]\] and the power of the study was \> 80% to detect associations of SNPs (dominant model) with a minor allele frequency ≥ 0.11 and a genotype relative risk ≥ 1.6. Benjamini-corrected false-discovery rate was employed to control for multiple hypothesis testing (MHT) \[[@B13]\].

Results
=======

The distribution of genotypes was consistent with Hardy-Weinberg equilibrium for all SNPs. No differences were found in the age and sex distribution and in the frequency of genotypes between diabetic and non-diabetic subjects (Table [1](#T1){ref-type="table"}). The characteristics of the patients according to GFR status are depicted in Table [2](#T2){ref-type="table"}. Patients with GFR \< 60 mL/min/1.73 m^2^are older, present longer diabetes duration, higher frequency of hypertension and of use of lipid lowering drugs, higher plasmatic concentrations of triglycerides and lower plasmatic concentrations of HDL-cholesterol.

###### 

Frequency of *CYBA*- 657 T → A (unregistered), *GCLC*- 129 C → T (rs17883901) and *GPX3*- 65 T → C (rs8177412) polymorphisms in type 1 diabetes patients and non-diabetic control subjects.

  ----------------------------------------------------------------------------------------------
                                    Non-diabetic control subjects\   Type 1 diabetes patients\
                                    n = 118                          n = 401
  --------------------------------- -------------------------------- ---------------------------
  **Sex (male/female)**             44.2%/54.8%                      49.5%/50.5%

                                                                     

  **Age (years)\***                 36 (29-44.5)                     34.7 (27.8-43)

                                                                     

  **- 675 T → A *CYBA*genotypes**                                    

                                                                     

   T/T                              101 (85.6%)                      351 (87.5%)

                                                                     

   T/A                              17 (14.4%)                       47 (11.7%)

                                                                     

   A/A                              0 (0%)                           3 (0.8%)

                                                                     

  **- 129 C → T *GCLC*genotypes**                                    

                                                                     

   C/C                              97 (82.2%)                       333 (83%)

                                                                     

   C/T                              21 (17.8%)                       64 (16%)

                                                                     

   T/T                              0 (0%)                           4 (1%)

                                                                     

  **- 65 T → C *GPX3*genotypes**                                     

                                                                     

   T/T                              87 (73.7%)                       298 (74.3%)

                                                                     

   T/C                              28 (23.8%)                       98 (24.5%)

                                                                     

   C/C                              3(2.5%)                          5 (1.2%)
  ----------------------------------------------------------------------------------------------

\*median ± interquartile interval.

###### 

Characteristics of type 1 diabetes patients according to the Glomerular Filtration Rate (GFR) status.

  ------------------------------------------------------------------------------------------------------------------------
                                        GFR ≥ 60 mL/min/1.73 m^2^(n = 265)   GFR \< 60 mL/min/1.73 m^2^\   *p*value
                                                                             (n = 136)                     
  ------------------------------------- ------------------------------------ ----------------------------- ---------------
  Sex (male/female) (%)                 42/58                                50/50                         0.1410

                                                                                                           

  **Age (years)**                       **33 (25.7-42.8)**                   **38 (30.8-45.6)**            **0.003**

                                                                                                           

  Age at diabetes diagnosis (years)     11.5 (6-18)                          13 (9-20.7)                   0.1206

                                                                                                           

  **Duration of diabetes (years)**      **20.6 (16.1-25.1)**                 **23 (18-31)**                **0.0086**

                                                                                                           

  **Arterial hypertension (%)**         **36.7**                             **64.5**                      **\< 0.0001**

                                                                                                           

  **Use of lipid-lowering drugs (%)**   **16.4**                             **25.3**                      **0.0325**

                                                                                                           

  Use of ACE inhibitors (%)             21.7                                 21                            0.8591

                                                                                                           

  HbA~1~C (%)                           8.25 (7.4-9.7)                       8.4 (7.4-9.8)                 0.7027

                                                                                                           

  Cholesterol (mg/dL)                   172 (149-199)                        179 (151-211)                 0.1437

                                                                                                           

  **HDL cholesterol (mg/dL)**           **58 (49-69)**                       **52 (43-64.2)**              **0.0134**

                                                                                                           

  LDL cholesterol (mg/dL)               91 (76-113)                          103 (78-129)                  0.0634

                                                                                                           

  **Triglycerides (mg/dL)**             **71 (53-107)**                      **98 (72-145)**               **\< 0.0001**
  ------------------------------------------------------------------------------------------------------------------------

Data are median ± interquartile interval; ACE: angiotensin converting enzyme; GFR: glomerular filtration rate.

No statistically significant differences were found in frequency of the genotypes T/C+C/C of the SNP *GPX3*rs8177412 between patients with and without overt DN (29.8% and 24%, respectively) and between patients with GFR \< and ≥ 60 mL/min/1.73 m^2^(28.4% and 24%, respectively) (data not shown).

The characteristics of the patients according to the genotypes of SNPs *CYBA*-675 A → T and *GCLC*rs17883901 are depicted in Table [3](#T3){ref-type="table"}. The frequency of overt DN was significantly lower in the group of patients carrying *CYBA*genotypes T/A+A/A (20%) than in the group carrying the T/T genotype (36.2%) (*p*= 0.0398) but this association lost significance if corrected for MHT. The frequency of GFR \< 60 mL/min/1.73 m^2^was also significantly lower in the group of patients carrying genotypes T/A+A/A (18.7%) than in the group carrying the T/T genotype (35.3%) (*p*= 0.0143). Regarding *GCLC*rs17883901, the frequency of GFR \< 60 mL/min/1.73 m^2^was significantly higher in the group of patients carrying genotypes C/T+T/T (47.1%) than in the group carrying the C/C genotype (31.1%) (*p*= 0.0082). Both associations remained significant after correction for MHT. *GCLC*C/T+T/T genotypes were also associated with a significantly lower age at diabetes diagnosis (11 years old) in comparison to the C/C genotype (13 years old) (*p*= 0.0073) and with a higher frequency of use of angiotensin converting enzyme inhibitors (31.4% *versus*18.8%, respectively; *p*= 0.0164).

###### 

Characteristics of type 1 diabetes patients according to the genotypes of *CYBA*-675 T → A (unregistered) or *GCL*C rs17883901 SNPs.

  ----------------------------------------------------------------------------------------------------------------------------------------
                                          *CYBA*\          *CYBA*\           *P*value     *GCLC*\           *GCLC*\           *p*value
                                          TT\              TA+AA\                         CC\               CT+TT\            
                                          (n = 353)        (n = 48)                       (n = 331)         (n = 70)          
  --------------------------------------- ---------------- ----------------- ------------ ----------------- ----------------- ------------
  Sex (male/female) (%)                   45/55            43/57             0.4334       53/47             38/62             0.1259

                                                                                                                              

  Age (years)                             34.6 (27.7-43)   33 (27.8-43)      0.4778       35 (27.9-44)      34.6 (27.1-42)    0.6965

                                                                                                                              

  **Age at diabetes diagnosis (years)**   12 (7-19)        13 (10-19)        0.3466       **13 (7.5-20)**   **11 (7-15.2)**   **0.0073**

                                                                                                                              

  Duration of diabetes (years)            21 (16.4-26)     20.3 (16-27)      0.7917       21 (16.6-26)      21.6 (17-29.4)    0.6799

                                                                                                                              

  Arterial hypertension (%)               45.6             44.9              0.5250       46.1              43.4              0.3937

                                                                                                                              

  Use of lipid-lowering drugs (%)         19               15.7              0.3583       17.4              25.3              0.1336

                                                                                                                              

  **Use of ACE inhibitors (%)**           21.1             18.3              0.4068       **18.8**          **31.4**          **0.0164**

                                                                                                                              

  HbA~1~C (%)                             8.4 (7.4-9.6)    8.25 (7.2-10)     0.6329       8.3 (7.3-9.8)     8.3 (7.3-9.3)     0.9669

                                                                                                                              

  Cholesterol (mg/dL)                     173 (150-200)    180 (149.5-209)   0.4319       174 (149-201)     174 (157-197)     0.7560

                                                                                                                              

  HDL cholesterol (mg/dL)                 55 (46-67)       58 (47-69)        0.2954       57 (47-68)        52 (43-64.5)      0.0986

                                                                                                                              

  LDL cholesterol (mg/dL)                 95 (78-118)      97 (75.2-124.4)   0.7686       94.4 (78-119)     94.2 (78-116)     0.8902

                                                                                                                              

  Triglycerides (mg/dL)                   82 (58-118)      73 (54-113)       0.4712       80 (57-119.2)     85.5 (58-114.2)   0.3683

                                                                                                                              

  **Overt DN (%)**                        **36.2**         **20**            **0.0398**   33.6              40                0.2387

                                                                                                                              

  **GFR \< 60 mL/min (%)**                **35.3**         **18.7**          **0.0143**   **31.1**          **47.1**          **0.0082**
  ----------------------------------------------------------------------------------------------------------------------------------------

Data are median ± interquartile interval; ACE: angiotensin converting enzyme; DN: diabetic nephropathy; GFR: glomerular filtration rate.

Logistic regression analysis with GFR \< 60 mL/min/1.73 m^2^as dependent variable identified the presence of at least one A allele of the *CYBA*SNP as an independent protection factor against decreased GFR (OR = 0.38, CI95% 0.14-0.88, *p*= 0.0354) and the presence of at least one T allele of the *GCLC*rs17883901 SNP as an independent risk factor for decreased GFR (OR = 2.40, CI95% 1.27-4.56, *p*= 0.0068). Longer diabetes duration, arterial hypertension and higher triglycerides concentrations were also identified as independent risk factors for a GFR \< 60 mL/min/1.73 m^2^(Table [4](#T4){ref-type="table"}).

###### 

Logistic regression analyses with glomerular filtration rate \< 60 mL/min/1.73 m^2^as dependent variable.

                                    *OR*       *CI 95*         *p value*
  --------------------------------- ---------- --------------- ------------
  Age at diabetes diagnosis         1.52       0.90-2.59       0.1139
                                                               
  **Duration of diabetes**          **2.08**   **1.22-3.59**   **0.0075**
                                                               
  Female sex                        1.35       0.80-2.27       0.2521
                                                               
  **Arterial hypertension**         **1.98**   **1.18-3.33**   **0.0098**
                                                               
  HbA~1~C                           1.19       0.70-2.03       0.5060
                                                               
  Cholesterol concentrations        1.51       0.89-2.56       0.1256
                                                               
  **Triglyceride concentrations**   **2.30**   **1.30-4.10**   **0.043**
                                                               
  ***CYBA*(TA+AA)**                 **0.38**   **0.14-0.88**   **0.0354**
                                                               
                                                               
                                                               
  Age at diabetes diagnosis         1.50       0.88-2.56       0.1296
                                                               
  **Duration of diabetes**          **1.98**   **1.16-3.39**   **0.0116**
                                                               
  Female sex                        1.50       0.89-2.52       0.1215
                                                               
  **Arterial hypertension**         **1.98**   **1.18-3.33**   **0.0090**
                                                               
  HbA~1~C                           1.15       0.68-1.95       0.5792
                                                               
  Cholesterol concentrations        1.39       0.82-2.35       0.2176
                                                               
  **Triglyceride concentrations**   **2.47**   **1.40-4.38**   **0.0018**
                                                               
  ***GCLC*(CT + TT)**               **2.40**   **1.27-4.56**   **0.0068**

OR- Odds ratio; CI- confidence interval.

Discussion
==========

In the current study, the presence of at least one A allele in -675 T → A SNP and at least one T allele in rs17883901 located, respectively, at the promoter region of the *CYBA*and *GCLC*genes modulate the risk for decreased GFR in type 1 diabetes patients even after adjusting for other risk factors.

The participation of NOX-derived ROS in DN has been previously demonstrated in experimental models of diabetes \[[@B6],[@B14]\] while the contribution of genes coding proteins belonging to the NADPH system to genetic predisposition for DN has been little explored. The association of one *CYBA*SNP (+242 C → T \[rs4673\]) with overt DN was previously demonstrated in type 1 diabetes patients \[[@B15]\]. We evaluated a different functional SNP,-675 T → A and the proportion of patients with GFR \< 60 mL/min/1.73 m^2^was significantly lower in the group of patients carrying genotypes T/A+A/A. Moreno et al. have previously associated the T allele of this SNP with essential hypertension and with a higher phagocytic NADPH-dependent O~2~^•-^production in Spanish subjects and they hypothesized that the presence of the T allele increases p22phox transcription by interfering with binding of the transcription factor hypoxia-inducible factor 1-α (HIF-1α) \[[@B10]\]. Because high glucose is able to increase expression of HIF-1α in the glomeruli of animal models of diabetes in conditions of normoxia \[[@B16]\], it is plausible that patients harboring the T/A+A/A genotypes do not present an increase in p22phox transcription rate as high as that observed in patients harboring the T/T genotype in response to HIF-α, which could result in lower ROS generation in conditions of hyperglycemia.

The T allele of the *GCLC*rs17883901 SNP was previously associated to myocardial infarction in the Japanese \[[@B8]\] and Italian \[[@B17]\] populations and to non-alcoholic steatohepatitis in a Brazilian series \[[@B18]\]. No previous studies have associated this SNP with any of the chronic microangiopathic complications of DM, but a study performed in a Swedish population of type 1 diabetes patients found that the C/T genotype was associated with higher anti-GAD autoantibody concentrations compared to the C/C genotype. The authors suggested that this SNP influences anti-GAD levels and perhaps diabetes age at onset \[[@B19]\]. The results of the present study also suggest an effect of this SNP on the age at diabetes onset since age at diabetes diagnosis among those harboring the C/T+T/T genotypes was significantly lower than among patients with the C/C genotype.

Mechanisms underlying the increased susceptibility of type 1 diabetes patients carrying the T allele of the *GCLC*rs17883901 SNP toward the presence of decreased GFR may be the inability to increase concentrations of the enzyme γ-CGS during oxidative stress, which would result in lower production of GSH and thus, increased susceptibility of cells exposed to chronic hyperglycemia to ROS-induced lesions.

This study widens the spectrum of candidate genes for DN belonging to oxidant and antioxidant pathways and corroborates the assumption that therapeutic approaches to improve antioxidant defenses may be a strategy to prevent or delay chronic diabetic complications. However the present findings should be interpreted in the context of limitations of cross-sectional studies and must be validated in larger populations sorted by different phenotypes of renal impairment to further evaluated if these genetic variants are more involved with the decline of GFR than with development of proteinuria or if the current findings only reflect the larger number of patients stratified by GFR than by albuminuria status, given that in this latter analysis, patients presenting normoalbuminuria had been excluded. Besides, the ethnic admixture that characterizes the Brazilian population may be a source of false-positive associations. Ninety percent of the patients of the present study defined themselves as Caucasoid, 7.3% as African descendants and 2.7% as Asian descendants, but previous genetic studies demonstrated that color, as determined by physical evaluation, is a poor predictor of genomic African ancestry in Brazilians \[[@B20]\]. Nevertheless type 1 DM is predominantly a disease of Caucasians and of populations with a great Caucasian genetic admixture \[[@B21]\] and the genotypic frequencies of the *GCLC*and *CYBA*SNPs observed in this Brazilian sample are similar to those reported in the representative Caucasian samples genotyped in the HapMap CEU and in the previous study of the *CYBA*SNP in a Spanish series \[[@B10]\], respectively.

Conclusions
===========

The functional SNPs -675 T → A in *CYBA*and rs17883901 in *GCLC*, probably associated with cellular redox imbalances, modulate the risk for renal disease in the studied population of type 1 diabetes patients. Furthermore, replication studies for these functional variants will need to be carried out.
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